335 related articles for article (PubMed ID: 24994909)
21. Preexisting Antibody-Dependent Cellular Cytotoxicity-Activating Antibody Responses Are Stable Longitudinally and Cross-reactive Responses Are Not Boosted by Recent Influenza Exposure.
Valkenburg SA; Zhang Y; Chan KY; Leung K; Wu JT; Poon LL
J Infect Dis; 2016 Oct; 214(8):1159-63. PubMed ID: 27493238
[TBL] [Abstract][Full Text] [Related]
22. Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways.
Jegaskanda S; Vanderven HA; Tan HX; Alcantara S; Wragg KM; Parsons MS; Chung AW; Juno JA; Kent SJ
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541850
[TBL] [Abstract][Full Text] [Related]
23. The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens.
Vanderven HA; Kent SJ
Immunol Cell Biol; 2020 Apr; 98(4):253-263. PubMed ID: 31914207
[TBL] [Abstract][Full Text] [Related]
24. Eliciting broadly protective antibody responses against influenza.
Kirchenbaum GA; Ross TM
Curr Opin Immunol; 2014 Jun; 28():71-6. PubMed ID: 24632083
[TBL] [Abstract][Full Text] [Related]
25. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
[TBL] [Abstract][Full Text] [Related]
26. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
27. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
[TBL] [Abstract][Full Text] [Related]
28. Tracking progress in universal influenza vaccine development.
Ostrowsky J; Arpey M; Moore K; Osterholm M; Friede M; Gordon J; Higgins D; Molto-Lopez J; Seals J; Bresee J
Curr Opin Virol; 2020 Feb; 40():28-36. PubMed ID: 32279026
[TBL] [Abstract][Full Text] [Related]
29. [Research progress and prospect of universal influenza vaccine].
Luo DY; Xue CY; Cao YC
Bing Du Xue Bao; 2013 Nov; 29(6):646-50. PubMed ID: 24520771
[TBL] [Abstract][Full Text] [Related]
30. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
[TBL] [Abstract][Full Text] [Related]
31. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza.
Huber VC; McKeon RM; Brackin MN; Miller LA; Keating R; Brown SA; Makarova N; Perez DR; Macdonald GH; McCullers JA
Clin Vaccine Immunol; 2006 Sep; 13(9):981-90. PubMed ID: 16960108
[TBL] [Abstract][Full Text] [Related]
32. Imprinting, immunodominance, and other impediments to generating broad influenza immunity.
Knight M; Changrob S; Li L; Wilson PC
Immunol Rev; 2020 Jul; 296(1):191-204. PubMed ID: 32666572
[TBL] [Abstract][Full Text] [Related]
33. Toward a universal influenza virus vaccine: prospects and challenges.
Pica N; Palese P
Annu Rev Med; 2013; 64():189-202. PubMed ID: 23327522
[TBL] [Abstract][Full Text] [Related]
34. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.
Schmitz N; Beerli RR; Bauer M; Jegerlehner A; Dietmeier K; Maudrich M; Pumpens P; Saudan P; Bachmann MF
Eur J Immunol; 2012 Apr; 42(4):863-9. PubMed ID: 22531913
[TBL] [Abstract][Full Text] [Related]
35. Shaping a universally broad antibody response to influenza amidst a variable immunoglobulin landscape.
Andrews SF; McDermott AB
Curr Opin Immunol; 2018 Aug; 53():96-101. PubMed ID: 29730560
[TBL] [Abstract][Full Text] [Related]
36. Imprinting and Editing of the Human CD4 T Cell Response to Influenza Virus.
Nelson SA; Sant AJ
Front Immunol; 2019; 10():932. PubMed ID: 31134060
[TBL] [Abstract][Full Text] [Related]
37. Prospects of HA-based universal influenza vaccine.
Hashem AM
Biomed Res Int; 2015; 2015():414637. PubMed ID: 25785268
[TBL] [Abstract][Full Text] [Related]
38. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.
Ozawa T; Jin A; Tajiri K; Takemoto M; Okuda T; Shiraki K; Kishi H; Muraguchi A
Antiviral Res; 2011 Sep; 91(3):283-7. PubMed ID: 21726583
[TBL] [Abstract][Full Text] [Related]
40. Effector mechanisms of influenza-specific antibodies: neutralization and beyond.
Sicca F; Neppelenbroek S; Huckriede A
Expert Rev Vaccines; 2018 Sep; 17(9):785-795. PubMed ID: 30145912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
